Showing results (201-210 of 2,280) with videos related to

Sort By:
Pageof 228
HIV Medicine|January 18, 2008
Comparison of two genotypic algorithms to determine HIV-1 tropismC Soulié, A Derache, C Aimé, et al.
HIV Medicine|September 1, 2007
A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administrationM R Loutfy, M Harris, J M Raboud, et al.
HIV Medicine|September 1, 2007
Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteersA D Luber, R Brower, D Kim, et al.
HIV Medicine|July 31, 2007
The management of dyslipidaemias in antiretroviral-treated HIV infection: a systematic reviewC McGoldrick, C L S Leen
HIV Medicine|July 31, 2007
Interactions between protease inhibitors and acid-reducing agents: a systematic reviewL Béïque, P Giguère, C la Porte, et al.
HIV Medicine|July 31, 2007
Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targetsL Normén, B Yip, J Montaner, et al.
HIV Medicine|July 31, 2007
Evaluation of the use of dried spots and of different storage conditions of plasma for HIV-1 RNA quantificationB Amellal, C Katlama, V Calvez
HIV Medicine|August 15, 2006
Community-onset methicillin-resistant Staphylococcus aureus in an urban HIV clinicD Skiest, K Brown, J Hester, et al.
HIV Medicine|August 15, 2006
CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microLD M Moore, R S Hogg, B Yip, et al.
HIV Medicine|August 15, 2006
A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophyM Bickel, S Zangos, V Jacobi, et al.
Pageof 228